Natuzzi (NYSE:NTZ) reported quarterly losses of €(0.02) per share. This is a 100 percent decrease over losses of €(0.01) per share from the same period last year. The company reported €116.90 million in sales this quarter. This is a 10.48 percent decrease over sales of €130.58 million the same period last year.
Alterity Therapeutics Announced Earlier ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson's disease (PD).
